Clinical Trials Browser

Phase 2 × donafenib × 90 days × Clear all

NCT07353827 2026-01-20

FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma

Phase 2 Not yet recruiting

Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT05348811 2026-01-06

HAIC Combined With Donafenib and Sintilimab for Unresectable ICC

Phase 2 Completed

Gastrointestinal

Cholangiocarcinoma